Guidelines

Guidelines are key to modern health and medical practice. Their recommendations are evidence-based and cover a wide range of topics - managing specific conditions, use of medicines in different settings or services and interventions to improve health.

We are keen to publicise the efforts and outputs of all our guideline Working Groups where we can. Guidelines in Practice publicise expert content on best clinical practice to primary care health professionals. They recently used our guidelines as an example of their value in‘Accredited guidance promotes excellence in rheumatology’. Elsewhere, they are also covered the BSR Guideline on tocilizumab in RA and how it could help practitioners and commissioners.

Below are three tables that set out the current status of all of BSR’s guidelines. New ones are being developed whilst others that already exist may be undergoing minor or major revisions. The remainder are in current use.

NICE has accredited the process used by BSR to produce its clinical guidance. Accreditation is valid for 5 years from February 2013.


For full details on our accreditation, visit nice.org.uk/accreditation.

Current guidelines Produced Due for revision
Management of Adults with ANCA associated vasculitis
BSR and BHPR guidelines for the management of adults with ANCA-associated vasculitis

Executive summary
Full guidelines
2014
NICE accredited
2017
Use of IV Tocilizumab in the treatment of adults with RA

Executive summary
Full guidelines
2013
NICE accredited
2016
Treatment of psoriatic arthritis with biologics

Executive summary
Full guidelines
Audit tool
2013
NICE accredited
2016
The use of Rituximab in rheumatoid arthritis

Executive summary
Full guidelines
2011 2016
Management of the hot swollen joint in adults

Executive summary
Full guidelines
Revision statement
2006
Renewed and accepted unchanged in 2012
2016


Guidelines under revision Due for publication
Safety of anti-TNF therapies in RA

Executive summary
Full guidelines
2016
Management of Giant Cell Arteritis

Executive summary
Full guidelines
2016
RA guidelines on eligibility criteria for first biologic therapy

Executive summary
Full guidelines
2016
Management of polymyalgia rheumatica

Executive summary
Full guidelines
2016
Guidelines for disease-modifying anti-rheumatic drug (DMARD) therapy

Executive summary
Full guidelines
2016
Management of Gout

Executive summary
Full guidelines
2016


New guidelines in development Due for publication
Management of SLE
Q2 2016
Management of Scleroderma
Q1 2016
Prescribing for rheumatological conditions in pregnancy and breastfeeding
Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids.
Part II: analgesics and other drugs used in rheumatology practice.

Q4 2015
Ankylosing spondylitis/spondyloarthropathies and biologics Q1 2016
Management of Sjögren’s Syndrome